Text Size

Oral BG9928 in Patients With Heart Failure and Renal Insufficiency (POSEIDON)

This study has been terminated.
(Company Decision)
Sponsor:
Information provided by:
Biogen Idec
ClinicalTrials.gov Identifier:
NCT00745316
First received: September 2, 2008
Last updated: March 4, 2010
Last verified: March 2010
History of Changes
  Purpose

The main purpose of this study is to determine the safety and tolerability of BG9928 when given at different doses to patients with heart failure and renal insufficiency.

This study will also explore:

  • Disease related quality-of-life
  • Exercise capacity
  • Renal function
  • Concomitant medications

Condition Intervention Phase
Heart Failure
Renal Insufficiency
 Drug: Tonapofylline
Drug: Placebo
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients With Heart Failure and Renal Insufficiency

Resource links provided by NLM:

MedlinePlus related topics: Heart Failure
Drug Information available for: Adenosine
U.S. FDA Resources

Further study details as provided by Biogen Idec:

Primary Outcome Measures:
  • To assess the safety and tolerability of BG9928 administered to subjects with heart failure and renal insufficiency. [ Time Frame: 16 Weeks ] [ Designated as safety issue: Yes ]

Enrollment: 34
Study Start Date: February 2009
Estimated Study Completion Date: January 2011
Estimated Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
oral Dose 1
 Drug: Tonapofylline
Oral Tonapofylline - 2 capsules bid
Other Name: Selective Adenosine A1 Receptor Antagonist
Experimental: 2
oral Dose 2
 Drug: Tonapofylline
Oral Tonapofylline - 2 capsules bid
Other Name: Selective Adenosine A1 Receptor Antagonist
Experimental: 3
oral Dose 3
 Drug: Tonapofylline
Oral Tonapofylline - 2 capsules bid
Other Name: Selective Adenosine A1 Receptor Antagonist
Experimental: 4
oral Dose 4
 Drug: Tonapofylline
Oral Tonapofylline - 2 capsules bid
Other Name: Selective Adenosine A1 Receptor Antagonist
Experimental: 5
oral Dose 5
 Drug: Tonapofylline
Oral Tonapofylline - 2 capsules bid
Other Name: Selective Adenosine A1 Receptor Antagonist
Placebo Comparator: 6
Placebo - 2 capsules bid
 Drug: Placebo
Oral placebo - 2 capsules bid

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Diagnosis of heart failure requiring hospitalization >1 and ≤12 months prior to screening
  • NYHA Class III or IV at the time of screening
  • Renal insufficiency as defined by eGFR ≥20 and ≤70 mL/min/1.73 m2
  • Negative pregnancy test

Exclusion Criteria:

  • History of an allergic reaction to any xanthine-containing compound.
  • History of seizure
  • History of stroke
  • Serious systemic infection
  • Sustained systolic blood pressure >170 or <90 mmHg
  • Myocardial infarction within 30 days of Day 1
  • Hemodynamically destabilizing arrhythmia within 30 days of Day 1
  • Uncorrected hemodynamically significant primary valvular disease
  • Known obstructive or restrictive cardiomyopathy
  • Cardiac surgery within 60 days prior to Day 1
  • Likely to undergo cardiac transplantation, device implantation, or other cardiac surgery within next three months
  • Evidence of malignancy within 6 months prior to Day 1.
  • Participation in any other investigational study of drugs or devices within 30 days prior to Day 1.
  • Receiving aminophylline, theophylline, pentoxifylline, dyphylline or adenosine
  • Presence of any clinically significant condition that might interfere with optimal safe participation in this study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00745316

  Show 30 Study Locations
Sponsors and Collaborators
Biogen Idec
Investigators
Study Director: Biogen Idec Medical Director Biogen Idec, Cambridge, MA USA
  More Information

No publications provided

Responsible Party: Biogen Idec, Medical Director, Biogen Idec
ClinicalTrials.gov Identifier: NCT00745316     History of Changes
Other Study ID Numbers: 161HF201
Study First Received: September 2, 2008
Last Updated: March 4, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Biogen Idec:
Heart Failure
Renal Insufficiency
Congestive Heart Failure

Additional relevant MeSH terms:
Heart Failure
Renal Insufficiency
Heart Diseases
Cardiovascular Diseases
Kidney Diseases
Urologic Diseases
Adenosine A1 Receptor Antagonists
 Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 19, 2013